Arcus Biosciences Forecast, price target & analysts
Arcus Biosciences Target price 2026 - Analyst rating & recommendation
Arcus Biosciences Classifications & Recommendation
Arcus Biosciences Price Target
| Target Price | $43.35 |
| Price | $24.44 |
| Potential |
77.37%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Arcus Biosciences 2027 .
The average Arcus Biosciences target price is $43.35.
This is
77.37%
register free of charge
$49.35
101.92%
register free of charge
$23.23
4.95%
register free of charge
|
|
| A rating was issued by 19 analysts: 15 Analysts recommend Arcus Biosciences to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arcus Biosciences stock has an average upside potential 2027 of
77.37%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 247.00 | 79.28 |
| 4.26% | 67.90% | |
| EBITDA Margin | -152.23% | -570.48% |
| 30.91% | 274.76% | |
| Net Margin | -142.91% | -587.88% |
| 30.29% | 311.35% |
14 Analysts have issued a sales forecast Arcus Biosciences 2026 . The average Arcus Biosciences sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Arcus Biosciences EBITDA forecast 2026. The average Arcus Biosciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Arcus Biosciences Analysts have issued a net profit forecast 2026. The average Arcus Biosciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.29 | -3.67 |
| 4.78% | 11.55% | |
| P/E | negative | |
| EV/Sales | 31.67 |
15 Analysts have issued a Arcus Biosciences forecast for earnings per share. The average Arcus Biosciences EPS is
This results in the following potential growth metrics and future valuations:
Arcus Biosciences...
Current Arcus Biosciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wedbush |
Locked
➜
Locked
|
Locked | Sep 30 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Sep 16 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 20 2026 |
| LifeSci Capital |
Locked
➜
Locked
|
Locked | Jun 04 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wedbush:
Locked
➜
Locked
|
Sep 30 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Sep 16 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 20 2026 |
|
Locked
LifeSci Capital:
Locked
➜
Locked
|
Jun 04 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
